[For the developments in the USA and Canada, refer to Cannabis: USA and Cannabis: Canada]
May 2026: Global Cannabis Prices Fall Sharply as Oversupply Intensifies Across Major Legal Markets
Cannabis prices continue to decline globally as legal markets mature, with structural oversupply, rapid capacity expansion, and regulatory fragmentation driving sustained price compression across North America and Europe.
In the United States, structural oversupply remains pronounced. Total legal production capacity is estimated at 600% of legal demand and 225% of total demand, including illicit consumption. This imbalance continues to place sustained downward pressure on wholesale and retail pricing across multiple states. As a result, industry profitability remains limited, with only about 27% of operators profitable in 2024.
The financial impact is also visible at the market level: U.S. legal cannabis revenues declined to an estimated range of $28.6 billion to $29.6 billion in 2024, down from $30.1 billion in 2023, marking the first recorded contraction in the history of the regulated U.S. cannabis market. Additionally, 24 U.S. states experienced revenue declines during the year, reflecting broader softness across mature and emerging state markets alike.
In Canada, oversupply conditions have led to significant inventory write-downs, with licensed producers reportedly destroying more than 425 metric tons of excess cannabis in a single year, highlighting the scale of production misalignment in a fully regulated national market.
In Germany, the medical cannabis market has expanded rapidly on the import side, with volumes increasing from 4.5 metric tons in 2018 to an estimated 201 metric tons in 2025, representing nearly a 45-fold increase over the period. Despite this growth in supply, prices have fallen by roughly 25% over the past two and a half years, reflecting increasing competition and widening supply-demand imbalance. Demand is estimated at 800,000 patients, while the import volume can now up to a million patients.
Despite these challenges, the global legal cannabis industry remains valued at $33-34 billion, with long-term growth expectations remain intact. The current phase of price compression is increasingly interpreted as a structural feature of market maturation rather than a cyclical downturn, with industry dynamics reflecting a transition from rapid legalization-driven expansion to efficiency-driven consolidation and normalization.
April 2026: Australia’s Medical Cannabis Boom Reverses as Regulatory Crackdown Hits Sales
Australia’s medical cannabis market is undergoing a sharp correction after a period of rapid expansion, with sales declining significantly as regulators tighten oversight of prescribing practices and industry conduct. The market had grown quickly to nearly A$1 billion in annual sales, supported by the rise of telehealth services and high-volume prescribing models. At its peak, Australians were spending more than A$400 million in just the first half of 2024, while total approvals surged to close to 1 million by the end of 2025, highlighting the scale and speed of the expansion.
Regulatory intervention – led by the Therapeutic Goods Administration (TGA) – is now targeting practices deemed overly commercial or insufficiently rigorous from a clinical standpoint. This includes scrutiny of high-volume prescribing clinics, tighter controls on repeat prescriptions, and enforcement against inappropriate advertising and promotional activity. As a result, the market has seen a marked downturn, with sales described as having plummeted amid reduced prescribing and disruption across distribution channels.
Overall, the shift reflects a transition from a fast-growing, access-driven market to a more tightly regulated medical framework, prioritizing clinical integrity over volume growth and materially impacting near-term industry performance.
March 2026: The International Medical Cannabis Market – Growth, Integration, and Digital Transformation
The international medical cannabis market – excluding the United States – has entered a period of rapid transformation. Over the past year, regulatory reforms, expanding trade, and the rapid scaling of digital healthcare delivery have reshaped both supply and demand across key regions. What was once a fragmented, early-stage industry is evolving into a more structured global marketplace, defined by a small number of dominant exporters, rapidly expanding patient markets, and increasingly sophisticated distribution channels.
At the heart of the international supply chain is Canada, firmly established as the world’s largest exporter of medical cannabis. In 2025, Canadian exports reached 275.3 metric tonnes – exceeding the combined total of all other exporting nations. This dominance stems from structural advantages: early legalization of adult-use cannabis created a large domestic market, allowing licensed producers to scale efficiently, refine operations, and achieve cost advantages that competitors find difficult to match. As a result, Canadian companies supply international markets consistently and at scale, serving Europe, Australia, and emerging patient markets. Other exporters – including Portugal and Israel – remain important players, though increasingly as part of a connected global supply chain rather than standalone leaders.
While cultivation remains central to value creation, production geography is shifting. Portugal, long seen as a European cultivation hub, is increasingly functioning as a processing and re-export center. Rather than relying solely on domestic growth, Portuguese operators import bulk cannabis – primarily from Canada – process it into finished or semi-finished products, and distribute them across European patient markets. This modular approach to supply – separating cultivation, processing, and distribution – reflects economic realities and regulatory preferences and underscores the importance for investors and operators of understanding where value is actually generated.
On the demand side, Europe has emerged as the focal point of global patient expansion, led by Germany and the United Kingdom. Germany is now the largest medical cannabis market outside North America, valued at nearly $1 billion in 2025. Growth has been fueled by regulatory reforms, including removal of cannabis from the narcotics list and simplified prescribing pathways, which have expanded patient access, increased prescriptions, and attracted new commercial operators.
The United Kingdom, while smaller, has seen comparable momentum. The market doubled in size to nearly $300 million in 2025, driven by rising patient awareness, expanding clinic networks, and growing physician acceptance. From a commercial perspective, the UK is notable for the speed of its development, transitioning from a marginal market to a major European player within a few years. Together, Germany and the UK account for the majority of European medical cannabis activity, setting the benchmark for regulatory and commercial development across the region.
Beyond Europe, several markets are contributing to global expansion. Australia continues to scale rapidly, supported by clear regulations and strong uptake of telemedicine. Brazil is emerging as a significant patient market, though it relies primarily on importation and prescription-based access. Other markets – including Poland, Thailand, and France – remain in earlier development stages but represent future growth opportunities as regulatory frameworks mature.
A defining trend is the rise of telemedicine as the primary access channel for patients. In Australia, Germany, the UK, and Brazil, digital-first clinics have become the main interface between patients and prescribers. This shift reflects regulatory flexibility and patient preference, reducing friction in prescribing, expanding geographic access, and enabling specialized clinics to scale rapidly. In many jurisdictions, telemedicine has effectively replaced traditional in-person pathways. The pattern is consistent: initial proliferation of teleclinic providers is followed by consolidation, as a small number of operators capture the majority of patients. These platforms increasingly influence prescribing behavior, product selection, and pricing – making them central to the commercial landscape.
The international medical cannabis market is transitioning from a fragmented, experimental phase to a more mature and globally integrated system. Three structural trends define this evolution:
– Concentration of supply, led by Canada’s export dominance
– Rapid growth in demand, particularly in Europe’s largest patient markets
– Digital-first access, with telemedicine at the center of patient engagement.
At the same time, evolving supply chains and emerging markets suggest the landscape will remain dynamic. Competitive positioning will increasingly depend on scale, regulatory expertise, and the ability to navigate multi-country value chains. As the industry matures, the gap between leading and lagging markets is likely to widen, making strategic market selection and operational flexibility key to long-term success.
March 2026: Europe’s Five Stages of Cannabis Legalization
Europe is moving toward cannabis legalization – but not in one leap. Instead, the continent is advancing through a series of cautious policy steps, each expanding access while testing political tolerance and regulatory frameworks. Germany’s legalization of recreational cannabis in April 2024 marked a turning point. As Europe’s largest economy, its move signaled that cannabis reform had shifted from the margins of policy debates into the mainstream of European governance. Yet the European approach differs sharply from the American model of rapid commercial expansion. In Europe, legalization has unfolded gradually, through a sequence of five distinct regulatory stages.
Together these stages form a ladder of reform – one that most European countries are climbing slowly and carefully.
Stage 1: Complete Prohibition
At the most restrictive end are countries where cannabis remains illegal for both recreational and medical use. Several European states still maintain strict prohibitionist policies, often reflecting conservative drug frameworks inherited from earlier decades. Countries such as Bulgaria, Hungary, Sweden, and Slovakia continue to enforce criminal penalties for possession. In much of Eastern Europe and parts of Scandinavia, political appetite for reform remains limited, though debates are slowly emerging. While this group is shrinking, it still represents a meaningful share of the continent, illustrating that Europe’s cannabis landscape remains far from uniform.
Stage 2: Pharmaceutical Cannabinoids
The first step away from outright prohibition typically comes through pharmaceutical cannabis-based medicines. In these jurisdictions, patients may access prescription drugs containing cannabinoids such as THC or CBD, but only in standardized pharmaceutical form. Products like Sativex or synthetic THC formulations are prescribed for specific medical conditions, often through hospital systems. Countries including Austria, Belgium, Finland, Ireland, and Poland fall into this category. The regulatory logic is familiar to European health authorities: cannabinoids are treated not as herbal products but as tightly controlled pharmaceuticals. This stage introduces cannabis into medical practice without opening the door to broader legalization.
Stage 3: Medical Cannabis Programs
The next step expands access from pharmaceutical preparations to botanical cannabis itself. Across much of Europe, medical cannabis programs now allow doctors to prescribe cannabis flower, oils, or extracts for patients suffering from chronic pain, epilepsy, or other qualifying conditions. Dispensing typically occurs through pharmacies under strict medical supervision. The United Kingdom, Italy, Portugal, Switzerland, Denmark, and Greece are among the countries operating such programs. In some cases, the systems remain limited or bureaucratic, with relatively small patient populations. Nevertheless, this stage has quietly built the foundation of Europe’s cannabis industry. Medical programs have created regulated supply chains, cultivation facilities, and pharmaceutical distribution networks across the continent.
Stage 4: Decriminalization and Toleration
Some countries have gone further by removing criminal penalties for personal possession, even while maintaining technical prohibitions. Spain and the Netherlands are the most famous examples. The Netherlands operates a longstanding “tolerance” policy under which licensed coffee shops can sell small quantities of cannabis, even though the product itself remains illegal under national law. Spain has developed a parallel system of private cannabis clubs that operate in a legal gray area. Other countries -including Estonia and Slovenia – have adopted forms of administrative decriminalization, replacing criminal charges with fines. These systems have produced thriving informal markets, demonstrating public demand while allowing governments to avoid fully embracing legalization.
Stage 5: Adult-Use Legalization
The final stage – full legalization for adult use – remains rare in Europe. Only four countries currently permit adults to legally possess and cultivate cannabis: Malta, Luxembourg, Germany, and the Czech Republic. Even these models are cautious compared with the United States or Canada. Rather than commercial dispensaries, European frameworks rely heavily on home cultivation and nonprofit cannabis clubs. Germany’s law, for instance, allows adults to possess up to 50 grams and grow three plants at home, while regulated social clubs distribute cannabis to members on a nonprofit basis. The approach reflects a distinctly European philosophy: legalization without commercialization.
| Adult Use Legal | Pharmaceutical Cannabinoids Only | Medical Cannabis | Decriminalized | Fully Illegal |
|---|---|---|---|---|
| Malta, Luxembourg, Germany, Czech Republic | Austria, Belgium, Croatia, Finland, Ireland, Liechtenstein, Poland, San Marino, Turkey | Cyprus, Czech Republic, Denmark, France, Greece, Italy, North Macedonia, Norway, Portugal, Romania, Switzerland, Ukraine, United Kingdom | Estonia, Netherlands, Slovenia, Spain | Andorra, Bulgaria, Bosnia and Herzegovina, Belarus, Hungary, Iceland, Kosovo, Lithuania, Latvia, Monaco, Moldova, Montenegro, Serbia, Slovakia, Sweden |
Despite rapid policy changes, Europe’s cannabis market remains modest compared with the United States and Canada. Legal cannabis sales across Europe reached roughly $1.7 billion in 2025 with projections pointing to a strong growth to around $4 billion by 2030. Germany alone accounted for nearly $1 billion in legal sales last year, making it the continent’s largest market. By comparison, the U.S. cannabis industry exceeds $30 billion annually, with dozens of states operating large retail markets. Yet investors increasingly view Europe as the next major frontier. Unlike the United States – where cannabis remains federally illegal – European cannabis markets typically operate within national legal frameworks. That regulatory clarity has attracted significant capital to cultivation hubs in countries such as Spain and Portugal, which export medical cannabis across the continent.
Europe’s cannabis revolution is unfolding slowly, but steadily. Rather than moving directly to commercial legalization, governments are progressing through incremental stages: from pharmaceutical cannabinoids, to medical programs, to decriminalization, and finally – only in a handful of cases – to adult-use legalization. It is a methodical, almost bureaucratic approach to reform. But step by step, the continent is turning green.
January 2026: Germany’s Medical Cannabis Boom: Prescriptions Surge, Prices Fall, and Product Choice Expands
Germany’s medical cannabis program has seen an extraordinary surge in prescriptions following regulatory changes that removed cannabis from the country’s narcotics list and made it easier to prescribe and access through telemedicine platforms. According to a recent report, by December 2025, prescriptions had increased by more than 3,300% compared with March 2024, the last month before cannabis was reclassified and distributed through more streamlined channels. This unprecedented growth reflects both simplified prescribing rules and the expansion of digital health services that connect patients with doctors and pharmacies.
At the same time that prescription volumes exploded, prices for medical cannabis flower fell significantly. The average price per gram declined from €8.33 in January 2025 to €5.23 in December 2025, a drop of more than €3 over the course of the year. This price compression has made medical cannabis more affordable for patients and has increased competitive pressure across the market.
Product availability has also expanded rapidly in tandem with demand and lower prices. Over the same period, the number of available cannabis flower products rose from 468 to 724, reflecting both greater import volumes and a broader range of strains and options being offered by distributors and pharmacies. Most of the newly available products are priced under €6 per gram, significantly shifting the market toward lower-cost options for treatment.
This rapid growth and changing market dynamics have drawn attention from policymakers and industry stakeholders, with debates emerging over how to balance access, medical oversight, and regulation – especially in the context of telemedicine prescriptions and evolving healthcare delivery models.
December 2025: Cronos Acquires Leading Supplier in Dutch Cannabis Pilot, Deepening Altria-Linked Presence in Europe
Canadian cannabis producer Cronos Group has agreed to acquire Dutch cannabis grower CanAdelaar for at least €57.5 million, giving Cronos a dominant position in the Netherlands’ regulated cannabis pilot program. The acquisition is expected to close in early 2026, subject to regulatory approvals, and strengthens Cronos’ presence in what it views as Europe’s largest adult-use cannabis market.
CanAdelaar is a key participant in the Dutch government’s cannabis pilot. The company supplies cannabis and hashish to most of the 72 coffeeshops participating in the program across ten municipalities. The pilot is designed to test whether the Netherlands can regulate cannabis production, distribution, and retail through a fully controlled supply chain. This represents a significant departure from the country’s long-standing tolerance policy, under which cannabis sales are permitted under certain conditions but products are sourced from illicit growers.
Cronos said the acquisition provides an entry point into a regulated European market and positions the company to benefit if the Dutch program is expanded to additional municipalities in the future. CanAdelaar currently supplies nearly all participating coffeeshops and is considered the largest producer operating within the pilot. The deal also highlights the involvement of major tobacco interests in the cannabis sector. Altria Group remains the dominant shareholder in Cronos with 41% stake with board representation and significant governance rights.
